临床试验研究设计终点和生物标志物药物安全性

关键字：类型：

下载页码(大于等于0,小于611)：

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

临床试验研究设计终点和生物标志物药物安全性 890条(本栏目收费,不能显示细节,电话13136136841)

classification,279–282 279 282

cytogenetics for diagnosis and prediction,299–310,314–315,323 299 310 314 315 323

endpoints in clinical trials event-free survival,311–313 311 313

relapse-free interval,313 313

Vara study,155–156 155 156

Weigelt study,156 156

flow chart,153–155 153 155

overview,152 152

rationale,155 155

non-inferiority trials,190 190

per protocol analysis comparison,146–149 146 149

run-in period,58,61,150 58 61 150

start date for endpoints,162–163 162 163

Interactive voice response system (IVRS)applications,125–126 125 126

concerns,126–128 126 128

Interferon-α adverse events,418–419 418 419

gene expression response,530–531 530 531

hepatitis C management,371,411–412,525–526 371 411 412 525 526

response,525–526,528–531 525 526 528 531

multiple sclerosis trial,407–408 407 408

Interferon-β multiple sclerosis management,408,508–509 408 508 509

Interferon-γ hepatitis C virus response,525–527 525 527

Chronic obstructive pulmonary disease (COPD)health-related quality of life,405 405

Cilloni study,320–322 320 322

Cisplatin black box warning,565–566 565 566

Cladribine multiple sclerosis management,509–510 509 510

origins,5–6 5 6

Clinical endpoint,191 191

Clinical research associate (CRA)functions,111,441 111 441

Clinical Review,601–602 601 602

最新招商产品更多>>

浙ICP备16010490号-2 增值电信业务经营许可证：浙B2-20220931　互联网药品信息服务资格证书编号：(浙)-经营性2023-0215　

浙公网安备:330683240604819103159
　医药代理商群１：

医药代理商群２：

医药代理商群３：